Chimerix, Inc.

Chimerix develops medicines to treat deadly diseases. Its pipeline products include ONC201 for glioma and neuroendocrine tumors, ONC206 for primary central nervous system tumors, and ONC212 for oncology indications. CMX521 is a treatment for SARS-CoV-2. The company also has a license agreement with SymBio Pharmaceuticals to develop TEMBEXA for human diseases. Chimerix was incorporated in 2000 and is headquartered in Durham, North Carolina.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

8.5 USD

Potential

-100%

Strengths

No significant strengths identified based on the analyzed metrics.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	0.3